Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
HealthDay News — Cytisine treatment fails to demonstrate noninferiority to varenicline treatment for smoking cessation, according to a study published in the July 6 issue of the Journal of the American Medical Association.
Ryan J. Courtney, PhD, from the University of New South Wales in Sydney, and colleagues compared effectiveness for standard cytisine vs standard varenicline treatment (84 days) for smoking cessation. The analysis included 1452 Australian adult daily smokers willing to make a quit attempt. Smokers were randomly assigned to either cytisine (725 participants; 1.5mg capsules taken 6 times daily then gradually reduced over the 25-day course) or varenicline (727 participants; 0.5mg tablets titrated to 1mg twice daily for 84 days).
The researchers found that verified 6-month continuous abstinence rates were 11.7% for the cytisine group and 13.3% for the varenicline group (risk difference, −1.62%; one-sided 95% CI, −5.02% to ∞; P =.03 for noninferiority). In the cytisine group, self-reported adverse events were less frequent (997 events among 482 participants vs 1206 events among 510 participants in the varenicline group), with an incidence rate ratio of 0.88 (95% CI, 0.81 to 0.95; P =.002).
“A possible reason why noninferiority was not achieved in the current trial is that the standard dosing and treatment length for cytisine may not be optimal,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Aflofarm, which is a manufacturer of cytisine.
